Supercharged immune cells take on advanced cancers in new trial
NCT ID NCT01697527
First seen Nov 26, 2025 · Last updated May 17, 2026 · Updated 18 times
Summary
This study tests a new approach for people with advanced cancers that have not responded to standard treatments. Doctors take a patient's own white blood cells, genetically reprogram them to recognize a protein called NY-ESO-1 found on cancer cells, and give them back along with a vaccine and stem cell transplant. The goal is to see if this helps the immune system shrink or control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of California at Los Angeles (UCLA )
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.